These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms. Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517 [TBL] [Abstract][Full Text] [Related]
8. Emergence of crenolanib for FLT3-mutant AML. Fathi AT Blood; 2013 Nov; 122(22):3547-8. PubMed ID: 24263951 [TBL] [Abstract][Full Text] [Related]
9. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. Jain T; Mesa R Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824 [TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243 [TBL] [Abstract][Full Text] [Related]
11. Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases. Cioccio J; Claxton D Expert Opin Investig Drugs; 2019 Apr; 28(4):337-349. PubMed ID: 30775933 [TBL] [Abstract][Full Text] [Related]
12. 2-Aminopyrimidine derivatives as selective dual inhibitors of JAK2 and FLT3 for the treatment of acute myeloid leukemia. Xu S; Zhu Y; Meng J; Li C; Zhu Z; Wang C; Gu YC; Han L; Wen J; Tong M; Shi X; Hou Y; Liu Y; Zhao Y Bioorg Chem; 2023 May; 134():106442. PubMed ID: 36878064 [TBL] [Abstract][Full Text] [Related]
14. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity. Langdon WY Crit Rev Oncog; 2012; 17(2):199-209. PubMed ID: 22471708 [TBL] [Abstract][Full Text] [Related]
15. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Maiti A; DiNardo CD; Daver NG; Rausch CR; Ravandi F; Kadia TM; Pemmaraju N; Borthakur G; Bose P; Issa GC; Short NJ; Yilmaz M; Montalban-Bravo G; Ferrajoli A; Jabbour EJ; Jain N; Ohanian M; Takahashi K; Thompson PA; Loghavi S; Montalbano KS; Pierce S; Wierda WG; Kantarjian HM; Konopleva MY Blood Cancer J; 2021 Feb; 11(2):25. PubMed ID: 33563904 [No Abstract] [Full Text] [Related]
16. Inhibition of c-Kit by tyrosine kinase inhibitors. Galanis A; Levis M Haematologica; 2015 Mar; 100(3):e77-9. PubMed ID: 25425690 [No Abstract] [Full Text] [Related]
17. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Hart S; Goh KC; Novotny-Diermayr V; Hu CY; Hentze H; Tan YC; Madan B; Amalini C; Loh YK; Ong LC; William AD; Lee A; Poulsen A; Jayaraman R; Ong KH; Ethirajulu K; Dymock BW; Wood JW Leukemia; 2011 Nov; 25(11):1751-9. PubMed ID: 21691275 [TBL] [Abstract][Full Text] [Related]
18. FLT3 inhibitors in acute myeloid leukemia: Current and future. Thomas CM; Campbell P J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754 [TBL] [Abstract][Full Text] [Related]
19. Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). Li Y; Wang P; Chen C; Ye T; Han Y; Hou Y; Liu Y; Gong P; Qin M; Zhao Y Bioorg Chem; 2020 Nov; 104():104361. PubMed ID: 33142418 [TBL] [Abstract][Full Text] [Related]